Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04003519

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

Non-interventional, Prospective Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Ipsen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to collect data about predictive factors for the efficacy of Lanreotide Autogel in patients with acromegaly in routine clinical practice.

Conditions

Timeline

Start date
2020-04-01
Primary completion
2023-06-30
Completion
2023-12-30
First posted
2019-07-01
Last updated
2020-06-02

Source: ClinicalTrials.gov record NCT04003519. Inclusion in this directory is not an endorsement.